7.2 Central Sleep Apnea, Cheyne-Stokes & Emergent Apneas

7.2 Central Sleep Apnea, Cheyne-Stokes & Emergent Apneas

Quick Answer: Central Sleep Apnea (CSA) is defined by the cessation of airflow due to a temporary absence of neural respiratory drive from the brainstem respiratory rhythm generator. It is fundamentally driven by high loop gain and hypocapnia, where arterial carbon dioxide drops below the apneic threshold during sleep transitions. Cheyne-Stokes Breathing (CSB) is a distinct form of CSA characterized by a crescendo-decrescendo breathing pattern with cycle lengths $\ge 40$ seconds, strongly linked to systolic heart failure (HFrEF) and prolonged circulation times. Treatment-Emergent Central Sleep Apnea (TE-CSA) occurs when central apneas (central AHI $\ge 5$/hr) emerge or persist during PAP titration once obstructive airway collapse is resolved; most cases resolve during the first 2–3 months of continued CPAP. Adaptive servo-ventilation (ASV) carries a safety warning for heart failure with $\text{LVEF} \le 45\%$ and predominant CSA based on the SERVE-HF trial, although the AASM's 2025 guideline allows carefully monitored use in experienced centers.

While obstructive sleep apnea involves physical collapse of the upper airway against ongoing respiratory effort, central sleep apnea represents a fundamental disorder of respiratory control. For the Clinical Sleep Health Specialist (CCSH), recognizing the underlying pathophysiology of central disordered breathing, identifying specific subtypes, and understanding advanced PAP therapy contraindications is crucial for clinical safety and therapeutic success.

---

Pathophysiology of Central Sleep Apnea: Loop Gain & The Apneic Threshold

Ventilation is regulated by a negative feedback control loop consisting of the central controller (medullary respiratory center in the brainstem, including the pre-Bötzinger complex), the actuators (phrenic motor neurons, diaphragm, and intercostal muscles), the plant (lungs, chest wall, and blood gas stores), and sensors (central chemoreceptors in the ventrolateral medulla sensitive to hydrogen ion concentration/$\text{PaCO}_2$, and peripheral chemoreceptors in the carotid bodies sensitive to $\text{PaO}_2$ and $\text{PaCO}_2$).

The "Wakefulness Drive to Breathe"

During wakefulness, breathing is maintained by two parallel inputs: the metabolic control system and non-chemical "wakefulness drives" (cortical, behavioral, and reticular activating system inputs). Because of this wakefulness drive, an awake individual continues breathing even if their arterial $\text{PaCO}_2$ drops significantly below normal basal levels.

Upon transitioning from wakefulness into non-rapid eye movement (NREM) sleep, the wakefulness drive abruptly extinguishes. Control of breathing becomes entirely dependent on metabolic chemical feedback. In NREM sleep, there exists an absolute hypocapnic apneic threshold—the specific $\text{PaCO}_2$ level below which central neural output to the diaphragm ceases completely.

In healthy adults, the eupneic (normal breathing) sleeping $\text{PaCO}_2$ is only 2 to 4 mmHg above the apneic threshold. If an individual hyperventilates—due to an arousal, reflex sigh, or high altitude—$\text{PaCO}_2$ drops. When $\text{PaCO}_2$ crosses below the apneic threshold, the brainstem stops firing, producing a central apnea. During the apnea, metabolic production of carbon dioxide causes $\text{PaCO}_2$ to rise. Once $\text{PaCO}_2$ rises back above the apneic threshold, respiratory drive resumes, often accompanied by an arousal and subsequent hyperventilation, setting off an oscillatory cycle.

The Components of Loop Gain

Loop gain ($LG$) measures the propensity of the ventilatory feedback control system to oscillate: $\text{Loop Gain} = \frac{\text{Ventilatory Response}}{\text{Ventilatory Disturbance}}$

• $LG < 1$: Stable, damped system. Disturbances quickly resolve.
• $LG \ge 1$: Unstable system. Minor disturbances trigger self-sustaining periodic breathing cycles.

Loop gain is governed by three primary components:

1. Controller Gain: Chemosensitivity of central and peripheral chemoreceptors. High controller gain means a tiny increase in $\text{PaCO}_2$ induces an exaggerated, explosive hyperventilatory response.
2. Plant Gain: The efficiency of the lungs and blood gas exchange in altering $\text{PaCO}_2$ for a given change in ventilation. Elevated in low functional residual capacity (FRC) states or low baseline $\text{PaCO}_2$.
3. Circulatory Delay: The transit time required for blood to travel from the pulmonary capillary bed to the carotid bodies and brainstem chemoreceptors. Prolonged circulatory delay introduces a phase lag, causing corrective hyperventilation to peak long after blood gas normalization has already occurred.

---

Cheyne-Stokes Breathing (CSB): Clinical Dynamics in Heart Failure & Stroke

Cheyne-Stokes Breathing (CSB) is a specific, severe manifestation of central sleep apnea characterized by repetitive cycles of waxing and waning tidal volumes (crescendo-decrescendo pattern) separated by central apneas or central hypopneas.

AASM Diagnostic Scoring Rules for CSB

To meet AASM criteria for Cheyne-Stokes breathing, the polysomnogram must demonstrate:

1. At least 3 consecutive central apneas and/or central hypopneas separated by a crescendo-decrescendo change in breathing amplitude, with a cycle length of at least 40 seconds (often 45 to 90 seconds); and
2. At least 5 central apneas and/or central hypopneas per hour of sleep associated with this pattern, recorded over at least 2 hours of monitoring.

For the ICSD-3 diagnosis of CSA with Cheyne-Stokes breathing, central events must also make up more than 50% of all apneas and hypopneas.

Pathogenesis in Heart Failure with Reduced Ejection Fraction (HFrEF)

In systolic heart failure, three pathophysiological abnormalities conspire to elevate loop gain and provoke CSB:

1. Marked Circulatory Delay: Severely reduced cardiac output and elevated left ventricular filling pressures prolong circulation transit time from the lungs to the carotid chemoreceptors (from a normal 10–15 seconds to 30–60+ seconds), causing severe phase lags in the feedback loop.
2. Pulmonary Congestion & Chronic Hyperventilation: Elevated pulmonary capillary wedge pressure stimulates unmyelinated vagal pulmonary J-receptors (juxtacapillary receptors), causing baseline tachypnea and chronic hyperventilation. Consequently, resting baseline awake and asleep $\text{PaCO}_2$ is chronically reduced (often $32\text{ to } 36\text{ mmHg}$), bringing resting $\text{PaCO}_2$ precariously close to the hypocapnic apneic threshold.
3. Elevated Controller Sensitivity: Enhanced peripheral chemoreceptor sensitivity amplifies the ventilatory response to minor carbon dioxide fluctuations.

CSB in Cerebrovascular Disease & Stroke

Cheyne-Stokes breathing occurs in up to $30\%$ to $50\%$ of patients following acute ischemic or hemorrhagic stroke, particularly involving hemispheric or supratentorial lesions. Cortical damage disrupts descending forebrain inhibitory pathways to the brainstem, releasing chemoreceptor sensitivity from cortical modulation and increasing controller gain.

---

Central Sleep Apnea Subtypes: Primary, High Altitude & Opioid-Induced

Medication-Induced CSA: The Opioid Crisis in Sleep Medicine

Exogenous opioids bind $\mu$-opioid receptors on respiratory pacemaker neurons in the pre-Bötzinger complex and parabrachial nucleus within the brainstem. This blunts both hypercapnic and hypoxic ventilatory responses and impairs regular respiratory rhythm generation. Opioid-induced disordered breathing manifests as ataxic breathing (Biot respiration—irregular periods of variable tidal volume interspersed with unpredictable central apneas) rather than smooth crescendo-decrescendo waves, and often features prolonged end-expiratory central pauses lasting $>30$ seconds. Methadone is a frequent culprit; studies of methadone-maintenance patients report central sleep apnea in roughly one-third.

---

Treatment-Emergent Central Sleep Apnea (TE-CSA / CompSAS)

Treatment-Emergent Central Sleep Apnea (formerly termed Complex Sleep Apnea) is defined by the development or persistence of central apneas or central hypopneas during positive airway pressure (PAP) titration in a patient whose initial diagnostic study showed predominantly obstructive sleep apnea, once the obstructive airway collapsibility has been largely eliminated.

Diagnostic Thresholds (ICSD-3)

1. Diagnostic sleep study confirms predominantly Obstructive Sleep Apnea (obstructive events exceed central events).
2. During PAP titration (CPAP or APAP), obstructive events are largely controlled, but central apneas or hypopneas emerge or persist.
3. The scored central AHI on PAP is $\ge 5.0\text{ events/hour}$, accounting for $\ge 50\%$ of total residual respiratory events.

Pathophysiological Mechanisms

• Elimination of Upper Airway Resistance: Relieving pharyngeal occlusion suddenly allows higher tidal volumes, washing out arterial carbon dioxide and driving $\text{PaCO}_2$ below the apneic threshold.
• Hering-Breuer Reflex Stimulation: Elevated continuous airway pressure distends pulmonary stretch receptors, transmitting inhibitory afferent signals via the vagus nerve to the brainstem to suppress phrenic inspiratory firing.
• PAP-Induced Unintentional Leak: High mask leaks trigger reflex hyperventilation and arousals, dropping $\text{PaCO}_2$.

Clinical Trajectory & Management

• Spontaneous Resolution: In most patients, treatment-emergent CSA is transient and fades during the first 2–3 months (often cited as 8–12 weeks) of continued CPAP as ventilatory control adapts and sleep consolidates. A minority persist, and a few patients develop central events later in treatment.
• Clinical Strategy: Clinical sleep health specialists should avoid premature modality switching on night one. First-line management involves eliminating mouth and mask leaks, avoiding over-titration of CPAP pressure, and encouraging continued CPAP use with close cloud-based adherence monitoring.
• Persistent TE-CSA: When central events persist beyond about 2–3 months and cause sleep disruption, sleepiness or poor tolerance, the physician may escalate to bilevel PAP with a backup rate (BPAP-ST) or ASV, both conditionally suggested in the AASM 2025 guideline.

---

Adaptive Servo-Ventilation (ASV) & The SERVE-HF Safety Alert

Adaptive Servo-Ventilation (ASV) is an advanced closed-loop positive airway pressure modality designed specifically to treat central sleep apnea and periodic breathing. ASV monitors patient ventilation on a breath-by-breath basis. During hyperpnea, ASV provides minimal pressure support; when patient effort wanes during hypopnea or central apnea, ASV dynamically increases inspiratory pressure support (IPAP) and delivers a mandatory backup rate to maintain a target minute ventilation ($90\%$ of recent moving average).

What Has Changed Since SERVE-HF

• ADVENT-HF (2024) tested a different, peak-flow-targeted ASV algorithm in heart failure with LVEF ≤45% and found no increase in mortality, although ASV did not improve the primary outcome.
• AASM 2025 central sleep apnea guideline: conditionally suggests ASV for primary CSA, CSA due to heart failure, medication- or substance-related CSA, treatment-emergent CSA and CSA due to a medical condition. Decisions should rest on expected improvement in symptoms or quality of life, and ASV in heart failure with reduced ejection fraction should be limited to experienced centers with close monitoring.
• For the CCSH: before an ASV setup, confirm that the prescriber has a current ejection fraction on file and has documented the heart-failure review. On the exam, an ASV order for a patient with LVEF ≤45% and predominant CSA should trigger this safety check.